Edwards Lifesciences Corporation Common Stock (EW)
Stock · NYSE · Health Care
$86.6as of 10/16/2026
Price chart
Active signals
No technical signal is currently active for this symbol.
EW Signal Track Record
How signals performed across all stocks →What EW's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 31 | +1.3% | 52% | September 16, 2026 |
| Bollinger Band Breakout | 20 | +0.7% | 50% | August 11, 2026 |
| Bollinger Band Breakdown | 17 | +4.0% | 53% | September 8, 2026 |
| 200-Day Moving Average Touch | 15 | +5.2% | 80% | October 1, 2026 |
| Any 20-session window (baseline) | +0.7% | 54% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About EW
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricu…
- Sector
- Health Care
- Industry
- Industrial Specialties
- Employees
- 16,000
- Website
- www.edwards.com
Fundamentals
- 1-day range
- $85.07$86.77
- Market cap
- $51.48B
- P/E (trailing)
- 49.06
- P/E (forward)
- 25.25
- EPS (trailing)
- $1.73
- Dividend yield
- —
- Beta
- 0.83
- Avg. volume
- 3.84M
How Edwards Lifesciences Corporation Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Feb 25, 2026 · via SEC EDGAR / Finnhub
Forecasts
26 analyst ratings
Edwards Lifesciences Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- EWEdwards Lifesciences Corporation Common Stock$86.6▼ 1.70%Market cap $51.48BP/E 49.06$72.3$96.29
- STESTERIS plc (Ireland) Ordinary Shares$222.66▼ 0.74%Market cap $22.62BP/E 27.15$195.14$269.44
- ZBHZimmer Biomet Holdings Inc. Common Stock$94.98▲ 0.64%Market cap $18.80BP/E 22.28$79.12$106.88
- MASMasco Corporation Common Stock$72.87▲ 0.40%Market cap $14.88BP/E 15.88$58.16$83.64
- AITApplied Industrial Technologies Inc. Common Stock$330.48▼ 1.00%Market cap $13.27BP/E 29.52$238.72$374.8
- SNNSmith & Nephew SNATS Inc. Common Stock$29.06▼ 0.10%Market cap $12.61BP/E 18.34$980.4$1,427
- ALGNAlign Technology Inc. Common Stock$147.31▼ 1.36%Market cap $12.11BP/E 25.36$126.33$200.44
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| EW Edwards Lifesciences Corporation Common Stock | $51.48B | 49.06 | $86.6 | ▼ 1.70% | $72.3$96.29 |
| STE STERIS plc (Ireland) Ordinary Shares | $22.62B | 27.15 | $222.66 | ▼ 0.74% | $195.14$269.44 |
| ZBH Zimmer Biomet Holdings Inc. Common Stock | $18.80B | 22.28 | $94.98 | ▲ 0.64% | $79.12$106.88 |
| MAS Masco Corporation Common Stock | $14.88B | 15.88 | $72.87 | ▲ 0.40% | $58.16$83.64 |
| AIT Applied Industrial Technologies Inc. Common Stock | $13.27B | 29.52 | $330.48 | ▼ 1.00% | $238.72$374.8 |
| SNN Smith & Nephew SNATS Inc. Common Stock | $12.61B | 18.34 | $29.06 | ▼ 0.10% | $980.4$1,427 |
| ALGN Align Technology Inc. Common Stock | $12.11B | 25.36 | $147.31 | ▼ 1.36% | $126.33$200.44 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Stay informed with the top movers within the S&P500 index on Thursday.ChartMill · 10/8/2026
- Barclays Initiates Coverage of Edwards Lifesciences at OverweightFintel · 10/7/2026
- Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?Yahoo · 10/7/2026
- Intel downgraded, Marvell upgraded: Wall Street's top analyst callsYahoo · 10/7/2026
- Edwards Lifesciences to Host Earnings Conference Call on November 4, 2026Yahoo · 10/7/2026
- Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110Benzinga · 10/7/2026
- Edwards Lifesciences to Host Investor Event in Conjunction With TCTYahoo · 10/5/2026
- Edwards Lifesciences Secures FDA Approval for First Expandable Pediatric Heart ValveBenzinga · 10/2/2026
Insider Activity
Insider Actions →- Daniel J. Lippis · October 8, 2026 · Option Exercise619 @ $72.68
- Daniel J. Lippis · October 8, 2026 · Sale619 @ $85.65
- Wayne Markowitz · September 14, 2026 · Tax Withholding568 @ $84.37
- Andrew M. Dahl · September 13, 2026 · Tax Withholding253 @ $84.37
- Wayne Markowitz · September 11, 2026 · Tax Withholding355 @ $86.77
- Daveen Chopra · September 11, 2026 · Tax Withholding398 @ $86.77
- Daniel J. Lippis · September 11, 2026 · Option Exercise619 @ $72.68
- Daniel J. Lippis · September 11, 2026 · Sale619 @ $87.51
- Andrew M. Dahl · August 31, 2026 · Sale544 @ $91.06
- Annette Bruls · August 28, 2026 · Sale2.6K @ $89.98
- Daveen Chopra · August 26, 2026 · Option Exercise31.8K @ $72.68
- Daveen Chopra · August 26, 2026 · Sale30.6K @ $90.99
- Daveen Chopra · August 26, 2026 · Sale1.2K @ $91.76
- Wayne Markowitz · August 26, 2026 · Sale1.2K @ $91.47
- Daniel J. Lippis · August 11, 2026 · Option Exercise619 @ $72.68
Institutional Ownership
March 31, 2026
- Total shares held
- 447.31M
- Total value held
- $34.71B
- Institutional holders
- 1272
- Unknown52.73M
- Unknown26.41M
- Unknown26.30M
- Unknown22.01M
- Unknown16.74M
- Unknown14.50M
- Unknown13.13M
- Unknown13.07M
- Unknown12.81M
- Unknown12.40M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
EW: FDA Flags High-Risk Device Recall After Patient Death
The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.
EW: FDA Flags High-Risk Device Recall After Patient Death. The U.S. Food and Drug Administration flagged a potentially high-risk issue with Edwards Lifesciences' SAPIEN M3 delivery system, specifically the Commander M system, after a patient death was reported. The company has instructed customers to remove four specific lots of the device from use. This regulatory action highlights a significant safety concern for the company's key product line, drawing close regulatory scrutiny.